Purchase this article with an account.
Jiwoong Lee, Hyocheol Lim; Incidence and risk factor of elevated intraocular pressure after dexamethasone intravitreal implant. Invest. Ophthalmol. Vis. Sci. 2016;57(12):3284.
Download citation file:
© ARVO (1962-2015); The Authors (2016-present)
To report the incidence of intraocular pressure (IOP) elevation and to identify the risk factors for IOP elevation after intravitreal dexamethasone 0.7mg (Ozurdex®) Implant.
A total 90 eyes of 83 patients who underwent intravitreal dexamethasone implantation and who were followed for ≥ 1 month were included. IOP elevation was defined as a pressure > 21 mmHg at some time during follow-up.
Twenty-seven eyes (30%) had an IOP greater than 21mmHg after dexamethasone intravitreal implant. The incidence of IOP elevation increases rapidly at 2~3 months after dexamethasone intravitreal implant. The Kaplan-Meier estimated incidence of IOP elevation was 26.8 ± 5.1% (mean±standard error) at 81 days. A Cox multivariate analysis showed the significant risk factors for IOP elevation to be age < 55 years (P = 0.023), baseline IOP ≥ 15mmHg (P = 0.002), a history of intraocular surgery (P＜0.001), and diabetic retinopathy (P = 0.026).
This study demonstrates the incidence of IOP elevation to be 26.8%, and describes the risk factors related to IOP elevation. Clinicians should be cautious about the possibility of IOP elevation after intravitreal dexamethasone implant, especially in the presence of identified risk factors.
This is an abstract that was submitted for the 2016 ARVO Annual Meeting, held in Seattle, Wash., May 1-5, 2016.
This PDF is available to Subscribers Only